Dr. Rakesh Popat, a consultant hematologist and associate professor at UCL, shares insights from ASH 2024 on myeloma and amyloidosis. He discusses the AQUILA trial, highlighting daratumumab's benefits for high-risk smoldering multiple myeloma. The conversation also covers the promising early data of Anito-Cel, a novel CAR T therapy, and updates on survival outcomes for cilta-cel in relapsed myeloma. Additionally, he reviews long-term advancements in treatment strategies for AL amyloidosis and ultra-high-risk myeloma patients.